VEXIM: Continued Sales Growth in Q1 2017

Posted On April 19, 2017 By OrthoSpineNews In Financial /

April 19, 2017

TOULOUSE, France–(BUSINESS WIRE)–Regulatory News:

VEXIM (Paris:ALVXM) (FR0011072602 – ALVXM), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces its consolidated Q1 sales results as of March 31^st, 2017.

« VEXIM sales performance in Q1 is in line with our expectations. VEXIM continues to gain market share in Europe and Internationally with a market growing around 5%. Our German business is also progressing and we remain confident to reach at least €5 million of sales there and rank among the top 3 market leaders. We maintain our guidance of 30% to 35% growth of sales and aim at reaching profitability for the full year 2017 », said Vincent Gardès, CEO of VEXIM.

Continued growth in the first quarter 2017

Revenue (€ in million – IFRS, as of March, 31^st)

Quarterly sales
Q1 2017	Q1 2016	Variation (%)
4.703	3.954	+19%

€4.7 million in sales, VEXIM continues to expand in all geographies

In Europe, Vexim’s business continues to grow and the SpineJack® is becoming progressively the standard of care for vertebral fractures. In France, its domestic market, Vexim continues to grow and increase its market shares. In Germany, the biggest market in Europe (worth €70 million per year), Vexim increased the size of its salesforce to meet the growing demand of the market, for its products. With the addition of Masterflow Plus, Vexim’s secondary product specifically designed for the German market and to address a large potential of patients suffering from osteoporotic compression fractures, Vexim also gained access to Clinicpartners, Agaplesion, AGKAMed and Paul Gerhard Diakonie, counting for 250+ clinics for Vexim to sell into. Vexim will furthermore initiate a clinical study in Germany where the Spinejack® will be more evidence based towards a wider range of indications to follow. In Germany, Vexim is then pursuing the objective of achieving €5.0 million of sales in 2017, and ranking among the top 3 market leaders in the country.

Italy will see Vexim grow to achieve a 20% market share position. With the approval by Sanitas in Spain, one of the largest insurance companies, Vexim expects to see a major step forward in its market expansion in 2017.

Outside of Europe, where sales in Q1 increased by 114% vs Q1 2016, Vexim continues to see growing interest in the SpineJack® technology. As previously announced, Vexim is in the process of launching Spinejack® products in Brazil, Australia and South Korea in the coming months.

Since its launch in 2011, the Spinejack® has now been implanted to more than 46 000 patients which is close to 22 000 surgeries.

Confirmation of 2017 guidance

First quarter 2017 revenues are in line with Vexim’s expectations. The group confirms his guidance for full year 2017 :

Sales growth of +30% to +35% (organic)
Positive operating and net income, throughout the full year
Sales of €5M Sales in Germany and rank among top 3 market leaders

Financial reporting schedule:
2^nd quarter sales: July 11^th, 2017¹

About VEXIM, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital², and from OSEO public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 66 members on its staff. VEXIM has been listed on NYSE Alternext Paris since May 3^rd 2012. For further information, please visit www.vexim.com

SpineJack®³, an innovative implant for treating Vertebral Compression Fractures
The SpineJack® is designed to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally invasive surgery, guided by X-ray, in approximately 30 minutes, which is intended to enable the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.

¹ Indicative date, subject to changes.
² Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.
³ This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.

Nom : VEXIM

Code ISIN : FR0011072602

Code mnémonique : ALVXM

Contacts

VEXIM
Vincent Gardès, CEO
José Da Gloria, Chief Financial Officer
Tel.: +33 5 61 48 48 38
investisseur@vexim.com
or
PRESS RELATIONS
ALIZE RP
Caroline Carmagnol / Wendy Rigal
Tel.: +33 1 44 54 36 66
Tel.: +33 6 48 82 18 94
vexim@alizerp.com

Shares of this surgical robot maker just jumped to an all-time high on better-than-expected earnings

Posted On April 19, 2017 By OrthoSpineNews In Financial, Robotics /

By: Lauren Thomas | @laurenthomasx3 CNBC / Market Insider with Patti Domm

Shares of Intuitive Surgical hit an all-time high Wednesday morning after the maker of the da Vinci surgery robot reported first-quarter earnings and sales that beat Street estimates.

The California-based company said it had earnings per share of $5.09 on sales of $674 million for the quarter, topping Thomson Reuters estimates for $4.93 on revenue of $669.7 million.

Important to Wall Street, Intuitive Surgical said Tuesday that it shipped 133 of its da Vinci surgical systems in the first quarter of 2017, compared with 110 robots delivered in the same period one year ago.

The stock traded up more than 7 percent, peaking at $811.89 per share Wednesday, and was on track for its best day since July 2015 when shares gained near 9 percent. Intuitive Surgical’s shares reached a low of $6 back in 2001.

READ THE REST HERE

Z-Medical LP appoints Chief Commercial Officer and Vice President Sales USA

Posted On April 19, 2017 By OrthoSpineNews In Spine /

Roswell, GA, April 7, 2017 – Z-Medical LP, subsidiary of Z-Medical GmbH + Co. KG, a privately financed and held medical device company that designs, develops, manufactures, and markets innovative implants and surgical instruments, announced today that it has appointed René Rothacker as Chief Commercial Officer and Jim Talbert as Vice President Sales USA.

Z-Medical received FDA 510(k) clearance to market the MIS Z-Pedicle Screw System in 1Q15, and established a U.S. subsidiary later that year to support launch with logistic partner WebOps, LCC and GlobalMed Logistix, LLC. In 4Q16, the company entered into an agreement with InterMed Resources tn, LLC to distribute the MIS Z-Pedicle Screw to HealthTrust’s ~1,600 acute care facilities in the U.S.

Mr. Rothacker will report directly to Alexander Henninger, CEO of Z-Medical LP and shareholder of Z- Medical GmbH + Co. KG. René Rothacker is responsible for leading the commercialization of Z-Medical’s MIS Z-Pedicle Screw System including sales and product promotion to drive US business growth.

He has over 15 years of experience in Marketing and Product Management in the medical device industry with an expertise in pharmaceutical packaging and spinal implants. Prior to joining the company, he was Consultant for Z-Medical and provided technical expertise and training in support of product development. Prior to this role he worked as Product Marketing Manager at joimax® GmbH, the leading developer and provider of complete systems for minimally invasive endoscopic spinal surgery and as Senior Product Manager at Paradigm Spine GmbH, a leader in the field of non-fusion spinal implant technology. He was responsible for defining product marketing strategies including preparation of international product launches as well as developing and implementing training programs for sales representatives, global distribution partners and surgeons. From 1999 to 2008, he was employed by Aptar Pharma (former Ing. Erich Pfeiffer GmbH) and was responsible for coordination of international customer projects, product training and support of the global distribution network. 2002, he received his Diploma in Business Administration and Engineering at the University of Cooperative Education at DHBW Stuttgart Campus Horb.

In his previous position as Director International Business Development at Z-Medical he was responsible and the main driver in setting up Z-Medical’s US Operation including the strategic partnership with WebOps, LCC and GlobalMed Logistix, LLC who provide Z-Medical with a comprehensive set of operational processes, tools and services for the US commercialization of MIS Z-Pedicle Screw System.

In this position he has worked in close cooperation with Mr. Talbert who is renowned within the Orthopedic, Neurosurgical, and Spine Industries as a decisive leader and a formidable force in international and regional markets. He formerly was Z-Medical’s USA National Distributor and supported Z-Medical in the start-up phase with his proven history of success in sales and product promotion, with a unique talent for building and maintaining business relationships. He will report to René Rothacker.

The strategic partnership with InterMed Resources tn, LLC who distributes spinal implants manufactured by Z-Medical to HealthTrust Purchasing Group, L.P., a leading group purchasing and total cost management organization that serves nearly 1,600 acute care facilities nationwide was initiated by Jim Talbert. Under the agreement, Z-Medical sells its MIS Z-Pedicle Screw System at a contracted price for distribution to HealthTrust member facilities throughout the United States.

Jim Talbert has extensive experience in training medical professionals in the proper application of surgical equipment and medical devices and is a driven individual committed to developing professional and personal skills to their greatest potential.

His history as a dedicated and organized professional, committed to providing exceptional customer care and support to clients with industry leaders such as Amedica Corp., Exactech, Inc., Globus Medical, Inc., Johnson & Johnson, DePuy, Medtronic, Pfizer, Smith & Nephew, Stryker Corporation, Zimmer, and Zimmer Spine equipped Jim with an expansive knowledge in the surgical device industry.

“We are delighted to have René Rothacker as our CCO and Jim Talbert as VP Sales USA on board of our US team. Their combined expertise and experience in Marketing & Sales will drive our business growth in the US to continue the success in our direct markets.” Alexander Henninger, CEO Z-Medical LP.

“The Innovative Simplicity and high versatility of our MIS Z-Pedicle Screw System can be a game changer, in a technical but also in an economical aspect. It was designed for a straight forward approach and to reduce surgical steps. The preloaded set-screw makes it faster and easier with fewer problems (no cross- threading or tulip splay). The multifunctional system and innovative implant design reduces the OR time, minimizes potential risks and offers a wide range of treatment options.”

About the MIS Z-Pedicle Screw System

The MIS Z-Pedicle Screw System with only one instrument tray offers surgeons an ideal solution for their indication specific needs. The high versatility of the system, the pre-sterilized implants as well as the innovative screw design enables them to efficiently and cost effectively address the most common pathologies. It was specifically designed for a minimally-invasive approach but can also be used in open procedures. It is approved for Degenerative, Trauma, Tumor and Deformity application. Alignment after surgical correction of spondylolisthesis, reduction in fracture- and the derotation in scoliosis treatments are achieved directly with the pre-assembled set-screw, the long reduction thread and the especially designed uniplanar fracture- and deformity screws.

About Z-Medical

Based and founded in Tuttlingen in 2010, Z-Medical® GmbH + Co. KG is a privately financed and held medical device company that designs, develops, manufactures and markets innovative implants and surgical instruments in the section of Spine, Hand & Foot and Arthroscopy. The company’s U.S. subsidiary was established in Atlanta, Georgia, in August 2015. Z-Medical implants stand for precision, innovative simplicity and ready for surgery.

Z-Medical is actively recruiting regional distributors to capitalize on this expansion to its hospital network. For further information about Z-Medical, the MIS Z-Pedicle Screw System or distribution opportunities please contact,

Jim Talbert at j.talbert@z-medical.de

René Rothacker at r.rothacker@z-medical.de

or visit

www.z-medicalUSA.com

Z-Medical LP

1455 Old Alabama Road, East / Suite 115-A Roswell, GA 30076 / USA

Phone: (+1) 404 941 2022

Web: www.z-medicalUSA.com

Reports of the Death of the C1-C2 Facet Injection have Been Greatly Exaggerated

Posted On April 18, 2017 By OrthoSpineNews In Spine /

By Chris Centeno, M.D., CEO at Regenexx – April 16, 2017

In 1897, Mark Twain was on a speaking tour in London when an American newspaper started a rumor that he was gravely ill. This was soon followed by an obituary. When asked by an American reporter in London about his death, Twain quipped, “The reports of my death have been greatly exaggerated.” I feel the same about C1-C2 facet injections. The radiofrequency mob has been trying hard to kill off cervical facet injections for years and C1-C2 is low hanging fruit, but like Twain, I have to report the death of this procedure has been greatly exaggerated.

What is a Facet Joint and how Does RFA Work?

Sometime around the turn of this last century, we began to see the use of radiofrequency ablation (RFA) for neck pain due to damaged facet joints take off. What is RFA and what is a damaged facet joint?

You have 14 joints in the back part of your spine (7 on each side). These joints help to control neck motion. These little articulations about the size of a finger joint are commonly called “facet joints”. They can become injured or can get arthritis like any other joint in your body. When this happens they can become chronically painful.

While the injection of anti-inflammatory steroid into these joints was the most common way to treat this pain, about 2000 or so we began to see the rise of another form of treatment called RFA. This procedure uses a probe that heats up to burn away nerves around the painful joint. The idea is that once these pain carrying “wires” are “cut”, the pain will stop because it’s no longer being transmitted to the brain. This works pretty well and has been well researched to help chronic neck pain caused by a damaged facet joint. However, as you might imagine, you can’t just burn nerves that carry pain signals and not have consequences. This procedure can cause the joint to become more damaged (a Charcot joint) and in my experience can cause a cycle where the patient needs to be treated every 5-18 months forever. In addition, my personal observation is that these patients get more “brittle” with time. By that, I mean that when their pain returns it’s worse and easier to provoke than before RFA was begun.

The RFA Biz Plan

Radiofrequency is a great medical business. Not only do these patients need to come back every so often for a repeat treatment, but insurance companies pay more for RFA than a simple facet injection. In addition, there’s a third party vendor who gets to charge outrageous prices for disposable needles and new RF probes, which means that there’s lots of moolah around to sponsor conferences, pay physician thought leaders, and medical directors. Hence, knowing that money talks in medicine, it’s not hard to figure out why those thought leaders have been trying to get rid of facet injections (i.e. injecting a substance into the joint rather than burning the nerves around the joint). as the idea competes with RFA. However, with the advent of orthobiologics like PRP and stem cells, everything changes.

READ THE REST HERE

ulrich medical USA® Triples U.S. Spine Business

Posted On April 18, 2017 By OrthoSpineNews In Financial, Spine /

ST. LOUIS, April 18, 2017 /PRNewswire/ — ulrich medical USA, Inc., a medical device company focused on developing and commercializing musculoskeletal implant technologies in the United States, today reported full year 2016 financial results with a 15% top line revenue increase for the year ending December 31, 2016 and a 20% growth in EBITDA for the same period.

“In 2010, we announced that we were changing our commercial structure and diversifying our U.S. spine trauma business by entering the degenerative spine market segment. Since that time, we have tripled our revenue, added eleven new FDA-cleared implants to our product portfolio, and we have increased our annual U.S. case numbers by 247%,” said Erika Laskey, Chief Commercial Officer, ulrich medical USA. “Over 50% of our revenue is now done outside of the corpectomy space and we have also just delivered six consecutive years of explosive growth with a 6-year 18% revenue CAGR and 26% EBITDA CAGR.”

“We are extremely proud of our performance in the U.S. market and we are exceptionally grateful to our customers for their support,” said Hans Stover, President and Chief Executive Officer, ulrich medical USA. “As we continue to thrive in our 105th year as a privately held, family-owned and operated company, we are well positioned to continue to bring our technically-advanced products to the market for the benefit of both patients and surgeons who prefer best-in-class spinal implant technologies.”

For more information, please visit www.ulrichmedicalusa.com.

About ulrich medical USA, Inc.

ulrich medical USA, Inc. is a subsidiary of ulrich medical®, an innovative medical technology company headquartered in Ulm, Germany.

Company Contact: e.laskey@ulrichmedicalusa.com

SOURCE ulrich medical USA, Inc.

(PRNewsfoto/ulrich medical USA, Inc.)…

Humana Brings Value-Based Orthopedic Specialty Care to Indiana and Kentucky

Posted On April 18, 2017 By OrthoSpineNews In Recon /

April 18, 2017

LOUISVILLE, Ky. & FORT WAYNE, Ind.–(BUSINESS WIRE)–Humana Inc. (NYSE: HUM) is teaming up with eight orthopedic specialty groups in Indiana and Kentucky on an orthopedic value-based care model for Humana Medicare Advantage members undergoing total hip or knee joint replacement procedures.

Humana’s Total Joint Replacement Episode-Based Model is designed to improve quality, outcomes and cost across a person’s entire joint replacement episode of care. Humana will provide the orthopedic practices with robust data and analytics needed to better manage all aspects of their patients’ care from diagnosis to recovery. For the patient, this is expected to deliver a more coordinated care experience and to reduce complication rates and unnecessary readmissions after surgery.

In Indiana, Humana will work with Fort Wayne Orthopedics, Ortho NorthEast, Orthopaedic Associates Inc., Tri-State Orthopaedics and Unity Healthcare LLC.

In Kentucky, Humana will work with Commonwealth Orthopaedic Centers, Kentucky Bone and Joint Surgeons and Norton Orthopedic Specialists.

Humana has 30 years of experience partnering with primary care physicians in value-based arrangements. By focusing on quality and health, Humana experienced 20 percent lower costs in total in 2015 for members who were treated by doctors and other health care professionals in a value-based reimbursement model setting versus an estimation of original fee-for-service Medicare costs using the Centers for Medicare and Medicaid Services (CMS) Limited Data Set Files. Humana is now moving to apply the approach to specialties, such as orthopedics, where highly coordinated care supported by population health data has the ability to potentially improve outcomes, lower cost and deliver a better health care experience for patients.

The participating Indiana and Kentucky orthopedic groups join the 12 orthopedic groups in Ohio and Tennessee who joined Humana’s orthopedic value-based care model in 2016.

Humana’s model is similar to the State of Tennessee’s Innovation Model (SIM) Grant through CMS for Medicaid beneficiaries.

Through the new agreements, Humana’s population health capabilities, including patient data and analytics as well as chronic disease management and wellness programs, will complement the integrated care approach that each orthopedic group will employ with Humana members.

“Through our total joint replacement model, Humana is taking value-based care to the next level – from primary care to a more involved medical procedure,” said Chip Howard, Humana’s Vice President of Payment Innovation. “Humana’s approach is to provide orthopaedic surgeons the tools they need to coordinate all aspects of their patients’ diagnosis, treatment, recovery and rehabilitation to in turn improve quality, lower cost and create a better experience for our members.”

As of Dec. 31, 2016, Humana has 1.8 million individual Medicare Advantage members and 200,000 commercial members today who are cared for by 50,400 primary care providers, in more than 900 value-based relationships across 43 states and Puerto Rico. For more information, visit humana.com/accountable-care or www.humana.com/valuebasedcare.

About Humana

Humana Inc., headquartered in Louisville, Ky., is a leading health and well-being company focused on making it easy for people to achieve their best health with clinical excellence through coordinated care. The company’s strategy integrates care delivery, the member experience, and clinical and consumer insights to encourage engagement, behavior change, proactive clinical outreach and wellness for the millions of people we serve across the country.

More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at www.humana.com, including copies of:

Annual reports to stockholders
Securities and Exchange Commission filings
Most recent investor conference presentations
Quarterly earnings news releases and conference calls
Calendar of events
Corporate Governance information

More Information

Humana is a Medicare Advantage HMO, PPO and PFFS plan with a Medicare contract. Enrollment in any Humana plan depends on contract renewal. This information is not a complete description of benefits. Contact the plan for more information. Limitations, copayments and restrictions may apply. Benefits may change each year. Other providers are available in our network.

Humana Inc. and its subsidiaries (“Humana”) do not discriminate on the basis of race,color, national origin, age, disability or sex.

English: ATTENTION: If you do not speak English, language assistance services, free of charge, are available to you. Call 1-800-281-6918 (TTY: 711).

Español (Spanish): ATENCIÓN: Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-800-281-6918 (TTY: 711).

繁體中文 (Chinese): 注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1–800-281-6918 (TTY：711).

Contacts

Humana Inc.
Corporate Communications
Marina Renneke, APR, 602-760-1758
mrenneke@humana.com

AAEAAQAAAAAAAAvIAAAAJDliMTc3YjM0LTI2ZDAtNGU4OC04ZDkxLTUzMjVmMGUxYWU1Mg.jpg

Extremity Reconstruction Market : New Business Opportunities & Investment Research Report 2017 – 2025

Posted On April 18, 2017 By OrthoSpineNews In Extremities, Financial /

04-18-2017 – Health & Medicine, Press release from: TMR Research

The global market for extremity reconstruction is expected to witness a high level of growth in the next few years. The rising number of cases of abnormalities and injuries in the lower and upper extremity of the human body is one of the vital factors estimated to encourage the growth of the global market in the coming years. In addition, several advancements in the healthcare infrastructure are anticipated to accelerate the development of the market in the near future. The implant devices for different parts of the human body comprises the extremity reconstruction market in the coming years.

A tremendous rise in the geriatric population and the rising incidences of obesity and diabetes are some of the major factors that are estimated to fuel the development of the global extremity reconstruction market in the near future. Moreover, the increasing cases of osteoarthritis and rheumatoid are likely to accelerate the growth of the market in the coming years. The rising awareness regarding the benefits of small joint reconstruction implants among patients is predicted to encourage the growth of the global extremity reconstruction market in the next few years.

Request a Brochure of the Report @ www.tmrresearch.com/sample/sample?flag=B&rep_id=1175

Technological advancements and the availability of required infrastructure are projected to augment extremity reconstruction market in North America market in the next few years. The leading players operating in the extremity reconstruction market across the globe are emphasizing on introducing innovative implants in order to attract a large number of consumers and attain a leading position in the market. Additionally, the rising level of competition is predicted to expand the product portfolio and benefit the patients in the coming years.

READ THE REST HERE

Medtronic sells monitoring, recovery products business for $6.1 billion

Posted On April 18, 2017 By OrthoSpineNews In Financial /

By Christopher Snowbeck Star Tribune – April 18, 2017

Medtronic PLC is selling a large portion of its business in patient monitoring and recovery products to Ohio-based Cardinal Health Inc. for $6.1 billion.

The transaction, which is expected to close in the second quarter of Medtronic’s fiscal year 2018, lets it focus on higher-tech devices like pacemakers and heart defibrillators that have been its historical focus.

Medtronic acquired the medical technology products in its January 2015 merger with Covidien PLC.

The businesses being sold generated approximately $2.4 billion in revenue over the last four reported quarters, Medtronic said. Cardinal Health said the deal would shift 23 product categories and more than 10,000 employees.

“These products — while truly meaningful to patients in need — are best suited under ownership that can provide the investment and focus that these businesses require,” Omar Ishrak, Medtronic’s chief executive, said in a statement. “At the same time, we can put these proceeds to work, investing over the long-term in higher returning internal and external opportunities.”

Based in Ireland, Medtronic has its operational headquarters in Fridley and has large businesses selling heart devices, insulin pumps and products used in spine surgeries.

With headquarters in Dublin, Ohio, Cardinal Health sells a variety of medical products to hospitals, health systems and other clinical entities worldwide.

READ THE REST HERE

Implanet Announces Q1 2017 Revenue

Posted On April 18, 2017 By OrthoSpineNews In Financial /

April 18, 2017

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

IMPLANET (Paris:IMPL) (OTCQX:IMPZY) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces its revenue for the first quarter of 2017.

In € thousands – IFRS*	Q1 2017	Q1 2016	Change
Spine (JAZZ)	1,066	837	+27%
Knee + Arthroscopy	982	1,151	-15%
Total revenue	2,048	1,988	+3%

*Unaudited data

In Q1 2017, Implanet recorded a +3% increase in revenue to €2,048 thousand (versus €1,988 thousand in Q1 2016). Jazz® activity increased by +27% to €1,066 thousand (vs. €837 thousand) and accounted for 52% of total revenue (vs. 42%), offsetting the 15% decrease in Knee sales to €982 thousand (vs. €1,151 thousand) because of difficulties in Brazil.

In France, the United States and the rest of the world, Jazz® sales grew by +61% to €417 thousand, +3% to €415 thousand and +34% to €234 thousand respectively. In markets where the Company operates directly, the high-potential degenerative bone disorder segment (adult treatment) saw sales increase by +60% to €353 thousand, accounting for 42% of Jazz® sales (vs. 36% in Q1 2016). Implanet sold 2,032 Jazz® implants over the quarter (vs. 1,197), a 70% volume growth.

Ludovic Lastennet, CEO of Implanet, says:

“Our overall quarterly growth, whilst penalized by the decrease in Knee exports, shows a continuous improvement in Jazz® in terms of both its adoption by surgeons and its share of the Company’s product mix. We have laid the foundation of our current growth by intensifying our efforts regarding the recognition of the clinical value of JAZZ® and the comprehensive nature of our product range. Lastly, we have treated almost 4,000 patients and with more than 20,000 Jazz® implants since its launch. For 2017, we remain confident in our ability to sustain continued growth in Jazz® revenue and establish it as a benchmark in spine surgery. Regarding the Knee segment, we expect activity to stabilize during the second quarter of 2017.”

Next financial press release: Q2 2017 revenue, on July 18, 2017

Annual general meeting: the combined general meeting of Implanet will be held on May 5, 2017 at 10:00 AM CET at the Company headquarters: Technopole Bordeaux Montesquieu, Allée François Magendie, 33650 Martillac, France.
You are invited to participate in the voting of the resolutions. For further information, please send your contact details to: implanet@newcap.eu

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2016 sales of €7.8 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

Disclaimer
This press release contains forward-looking statements concerning Implanet and its activities. Such forward looking statements are based on assumptions that Implanet considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Implanet registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on April 26, 2016 under number R.16-035 and available on the Company’s website (www.implanet-invest.com), and to the development of economic situation, financial markets, and the markets in which Implanet operates. The forward-looking statements contained in this release are also subject to risks unknown to Implanet or that Implanet does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Implanet that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements.

This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for Implanet shares in any country.

Contacts

IMPLANET
Ludovic Lastennet, Tel. : +33 (0)5 57 99 55 55
CEO
investors@implanet.com
or
NewCap
Investor Relations
Florent Alba, Tel. : +33 (0)1 44 71 94 94
implanet@newcap.eu
or
NewCap
Media Relations
Nicolas Merigeau, Tel. : +33 (0)1 44 71 94 98
implanet@newcap.eu
or
AlphaBronze
US-Investor Relations
Pascal Nigen, Tel.: +1 917 385 21 60
implanet@alphabronze.net

$Vexim: New Product Launch MASTERFLOW™ PLUS, a new product targeted at low energy osteoporotic fractures$

Vexim: New Product Launch MASTERFLOW™ PLUS, a new product targeted at low energy osteoporotic fractures

Posted On April 18, 2017 By OrthoSpineNews In Spine /

April 18, 2017

TOULOUSE, France–(BUSINESS WIRE)–Regulatory News:

VEXIM (Paris:ALVXM) (FR0011072602 – ALVXM), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces the launch in Germany of its new product Masterflow™ Plus, a new product targeted at low energy osteoporotic fractures.

“With this new product developed specifically for the German market, we aim to further increase our penetration and growth in that region. Dedicated to low energy osteoporotic fractures, a high-volume yet lower-price market, Masterflow™ Plus is designed to be competitive in that area and to offer hospitals and physicians a valid alternative to treat osteoporotic compression fractures. Meanwhile, the SpineJack® will continue its penetration of the German market especially on high-energy and complex vertebral fractures where vertebral body restoration and spinal balance correction need to be applied. This investment demonstrates VEXIM’s objective of becoming a significant Spine Trauma leader in Germany providing hospitals, surgeons and patients with best treatment options“, said Vincent Gardès, CEO of VEXIM.

Masterflow™ Plus, a new product dedicated to Germany

Masterflow™ Plus is a new solution designed to treat Vertebral Compression Fractures (A1-type according to Magerl and AOSpine Classifications) in Osteoporotic Bone. Masterflow™ Plus allows a Controlled Cement Augmentation Procedure first through vertebral body height elevation, and second by stabilizing the fracture using Cohesion® Bone Cement injection. This new system also offers the opportunity to treat multiple vertebral levels in a single surgery when combined with the Masterflow™ Injection System. The injector Masterflow™, launched in 2015, is a sophisticated solution providing a controlled high viscosity cement injection, at a safe distance¹from the radiation field for multi-level procedures².

This new method using the Jack Device³ and Masterflow™ injector offers the possibility to restore fractured vertebrae sustainably and inject high viscosity cement safely into the vertebrae. The Jack Device will be removed and used again for a possible next level. The advantage is a controlled cavity creation and directed height restoration where it is needed. The surgeon can control the expansion of the device.

Masterflow^TM Plus is a competitive price solution for multi-level fracture treatments, based on the similar and patented concept of SpineJack®, yet functioning in unidirectional form and with less force-capabilities in its height restoration. The instrument is single-use and disposable and delivered in combination with a solid injection system that is capable of delivering high viscosity cement under complete control of flow to accommodate the surgeons in the operating room.

With the commercialization of the Masterflow^TM Plus in Germany, the biggest market in Europe (worth €70 million), we also gained access to Clinicpartners, Agaplesion, AGKAMed and Paul Gerhard Diakonie, counting for 250+ clinics for Vexim to sell into.

Financial reporting schedule:
2^nd quarter sales: July 11^th, 2017⁴

About VEXIM, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital⁵, and from OSEO public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The company also developed the MasterflowTM, an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure. The company counts 66 employees, including its own sales teams in Europe and a network of international distributors. VEXIM has been listed on NYSE Alternext Paris since May 3^rd 2012. For further information, please visit www.vexim.com

SpineJack®⁶, an innovative implant for treating Vertebral Compression Fractures
The SpineJack® is designed to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally invasive surgery, guided by X-ray, in approximately 30 minutes, which is intended to enable the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.

Nom : VEXIM
Code ISIN : FR0011072602
Code mnémonique : ALVXM

¹ Mehlman, Charles T., DiPasquale, Thomas G. Journal of Orthopaedic Trauma: August 1997 – Volume 11 – Issue 6 – pp 392-398 Radiation Exposure to the Orthopaedic Surgical Team During Fluoroscopy: “How Far Away Is Far Enough?”
² http://en.vexim.com/professionals/injection-system-masterflow/
³ The “Jack Device” is a Vertect product used under an exclusive distribution agreement by Vexim
⁴ Indicative date, subject to changes.
⁵ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.
⁶ This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.

Author: OrthoSpineNews

VEXIM: Continued Sales Growth in Q1 2017

Contacts

Shares of this surgical robot maker just jumped to an all-time high on better-than-expected earnings

Z-Medical LP appoints Chief Commercial Officer and Vice President Sales USA

Z-Medical LP

Reports of the Death of the C1-C2 Facet Injection have Been Greatly Exaggerated

What is a Facet Joint and how Does RFA Work?

The RFA Biz Plan

ulrich medical USA® Triples U.S. Spine Business

Related Links

Humana Brings Value-Based Orthopedic Specialty Care to Indiana and Kentucky

Contacts

Extremity Reconstruction Market : New Business Opportunities & Investment Research Report 2017 – 2025

Medtronic sells monitoring, recovery products business for $6.1 billion

Implanet Announces Q1 2017 Revenue

Contacts

Vexim: New Product Launch MASTERFLOW™ PLUS, a new product targeted at low energy osteoporotic fractures

Contacts